| Literature DB >> 25001465 |
Ignacio Melero1, Gustav Gaudernack2, Winald Gerritsen3, Christoph Huber4, Giorgio Parmiani5, Suzy Scholl6, Nicholas Thatcher7, John Wagstaff8, Christoph Zielinski9, Ian Faulkner10, Håkan Mellstedt11.
Abstract
The therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting these responses are entering clinical practice. Antitumour immunization is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery vehicles and routes of administration are not yet identified. Active immunotherapy must also address the immunosuppressive and tolerogenic mechanisms deployed by tumours. This Review provides an overview of new results from clinical studies of therapeutic cancer vaccines directed against tumour-associated antigens and discusses their implications for the use of active immunotherapy.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25001465 DOI： 10.1038/nrclinonc.2014.111
Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675